Table 2.

Current therapies that are under investigation for use in chronic lymphocytic leukemia.

Class	Agent	Target	Phase of study	Status	Side effects	Reference/ clinicaltrials.gov
Small molecules/ antibodies	Obinutuzumab	CD20	III	Completed	Transfusion-related reactions	NCT01680991
	BI 836826 (moAb 37.1)	CD37	I	Active, not recruiting	Liver enzymes	NCT01296932
	Otlertuzumab	CD37	I/II	NA	Infusion reaction, nausea, fatigue, diarrhea	(140)
	Blinatumomab	CD19	I	Recruiting	Cytokine release syndrome	NCT02568553
	Rituximab	CD20	II	Terminated	Nausea, heartburn, joint pain, diarrhea	NCT01625741
Kinase inhibitors	Idelalisib	PI3Kδ	III	Active, not recruiting	Pneumonitis, diarrhea	NCT01539291
	AMG319	PI3Kδ	I	Completed	Diarrhea	NCT01300026
	IPI-145	PI3Kγδ	I/II	Active, not recruiting	Pneumonitis, neutropenia	NCT02158091
	Ibrutinib	BTK	III	Active, not recruiting	Diarrhea	NCT02801578
	AVL-292	BTK	I	Completed	Cytopenia	NCT01351935
	ONO-4059	BTK	I	Completed	NA	NCT01659255
	Dasatinib	BCR-ABL, Src	II	Completed	Pleural effusion	NCT00438854
	Fostamatinib	SYK	I/II	NA	Fatigue, diarrhea, nausea	(140)
	GS-9973	SYK	I	Completed	NA	NCT01841489
	CC115	mTOR, DNA-PK	I	Active, not recruiting	Hyperglycemia	NCT01353625
	PRT-2070	SYK	I (pending)	NA	NA	NA
BCL-2 antagonists	ABT-199	BCL-2	II	Active, not recruiting	Neutropenia, tumor lysis syndrome	NCT02141282
Immunomodulators	Lenalidomide	Multiple	III	Terminated	Myelotoxicity, tumor flare, immunosuppression, thromboembolic events	NCT00751296
CARTs	CTL019	CD19	II	Recruiting	B cell depletion, cytokine release syndrome	NCT02228096

CARTs, chimeric antigen receptor transduced T cells; moAb, monoclonal antibody; PI3K, phosphoinositide 3-kinase; BTK, Bruton tyrosine kinase; mTOR, mammalian target of rapamycin; DNA-PK, DNA protein kinase; NA, not applicable.